Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2024-02-06 00:00:00 ET · period of report 2024-02-05 · accession 0000950170-24-011769 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-06 | 2024-02-05 | KLRS | Brainard Diana | CEO, Dir | S - Sale | $0.67 | -41.4K | 822.3K | -5% | -$27.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-05 | S | D | 41,421 | $0.67 | 822,321 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.66 to $0.6914. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |